NASDAQ:AMPH Amphastar Pharmaceuticals (AMPH) Stock Price, News & Analysis → Moonshot Coins for the Current Crypto Run (From Crypto 101 Media) (Ad) Free AMPH Stock Alerts $40.45 -0.69 (-1.68%) (As of 06/12/2024 ET) Add Compare Share Share Today's Range$40.39▼$41.9050-Day Range$38.65▼$43.4852-Week Range$38.43▼$67.66Volume287,545 shsAverage Volume424,579 shsMarket Capitalization$1.98 billionP/E Ratio14.00Dividend YieldN/APrice Target$66.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Amphastar Pharmaceuticals alerts: Email Address Amphastar Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.50 Rating ScoreUpside/Downside63.2% Upside$66.00 Price TargetShort InterestBearish10.30% of Float Sold ShortDividend StrengthN/ASustainability-2.21Upright™ Environmental ScoreNews Sentiment0.80Based on 7 Articles This WeekInsider TradingSelling Shares$188,075 Sold Last QuarterProj. Earnings Growth15.28%From $3.60 to $4.15 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.90 out of 5 starsMedical Sector15th out of 913 stocksPharmaceutical Preparations Industry4th out of 429 stocks 3.3 Analyst's Opinion Consensus RatingAmphastar Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 2 buy ratings, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageAmphastar Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.Read more about Amphastar Pharmaceuticals' stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted10.30% of the float of Amphastar Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverAmphastar Pharmaceuticals has a short interest ratio ("days to cover") of 10.3, which indicates bearish sentiment.Change versus previous monthShort interest in Amphastar Pharmaceuticals has recently decreased by 0.27%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldAmphastar Pharmaceuticals does not currently pay a dividend.Dividend GrowthAmphastar Pharmaceuticals does not have a long track record of dividend growth. Previous Next 3.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreAmphastar Pharmaceuticals has received a 46.92% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Subcutaneous human immunoglobulin", "Procainamide", "Epinephrine", and "Medroxyprogesterone acetate" products. See details.Environmental SustainabilityThe Environmental Impact score for Amphastar Pharmaceuticals is -2.21. Previous Next 2.7 News and Social Media Coverage News SentimentAmphastar Pharmaceuticals has a news sentiment score of 0.80. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.93 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Amphastar Pharmaceuticals this week, compared to 4 articles on an average week.Search InterestOnly 5 people have searched for AMPH on MarketBeat in the last 30 days. This is a decrease of -38% compared to the previous 30 days.MarketBeat Follows9 people have added Amphastar Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 13% compared to the previous 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Amphastar Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $188,075.00 in company stock.Percentage Held by Insiders27.10% of the stock of Amphastar Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions65.09% of the stock of Amphastar Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Amphastar Pharmaceuticals' insider trading history. Previous Next 4.4 Earnings and Valuation Earnings GrowthEarnings for Amphastar Pharmaceuticals are expected to grow by 15.28% in the coming year, from $3.60 to $4.15 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Amphastar Pharmaceuticals is 14.00, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 145.99.Price to Earnings Ratio vs. SectorThe P/E ratio of Amphastar Pharmaceuticals is 14.00, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 181.88.Price to Earnings Growth RatioAmphastar Pharmaceuticals has a PEG Ratio of 0.86. PEG Ratios below 1 indicate that a company could be undervalued.Price to Book Value per Share RatioAmphastar Pharmaceuticals has a P/B Ratio of 3.03. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Amphastar Pharmaceuticals' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Financial Markets DailyEstee Lauder, MAC, and other beauty brands are raving about this emerging NYSE AI companyA Little-known NYSE Company is Empowering the Beauty Industry with Innovative AI and AR Tools.Discover this unknown NYSE Tech SaaS company About Amphastar Pharmaceuticals Stock (NASDAQ:AMPH)Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company provides Amphadase, an injection to absorb and disperse other injected drugs; Epinephrine injection for allergic reactions; Lidocaine jelly, an anesthetic product for urological procedures; Lidocaine topical solution for various procedures; Phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products; morphine injection for use with patient-controlled analgesia pumps; and Lorazepam injection for surgery and medical procedures. In addition, it offers Neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; Isoproterenol hydrochloride injection for mild or transient episodes of heart block; Ganirelix Acetate injection for the inhibition of premature luteinizing hormone surges; Vasopressin to increase blood pressure; and Regadenoson, a stress agent for radionuclide myocardial perfusion imaging. Further, the company distributes recombinant human insulin APIs and porcine insulin API. Additionally, it develops generic product candidates, such as injectable, inhalation, and analytical technologies; biosimial product candidates; and intranasal epinephrine for the treatment of allergic reactions. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.Read More AMPH Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart AMPH Stock News HeadlinesJune 12 at 6:26 AM | insidertrades.comAmphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Director Sells $124,200.00 in StockJune 7, 2024 | insidertrades.comFloyd F. Petersen Sells 500 Shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) StockJune 12 at 6:30 AM | americanbankingnews.comAmphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Director Floyd F. Petersen Sells 3,000 SharesJune 4, 2024 | americanbankingnews.comAmphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Short Interest Down 5.5% in MayMay 30, 2024 | seekingalpha.comAmphastar Pharmaceuticals: Buy When Fear Is OverblownMay 28, 2024 | stocknews.com4 Pharma Stocks to Watch for Surprising Gains in JuneMay 25, 2024 | finance.yahoo.comAmphastar Pharmaceuticals, Inc. (AMPH)May 22, 2024 | markets.businessinsider.comAmphastar Pharmaceuticals Holds Steady Amidst New Approval and Competitive MarketMay 22, 2024 | finanznachrichten.deAmphastar Pharmaceuticals, Inc.: Amphastar Receives FDA Approval for Albuterol Sulfate Inhalation AerosolMay 22, 2024 | finance.yahoo.comAmphastar Receives FDA Approval for Albuterol Sulfate Inhalation AerosolMay 20, 2024 | seekingalpha.comAmphastar Pharmaceuticals: Profitable Pharma With Strong GrowthMay 16, 2024 | investorplace.comPatent Peril: 3 Stocks at Risk From the FTC's Drug CrusadeMay 15, 2024 | seekingalpha.comReassessing Amphastar PharmaceuticalsMay 15, 2024 | finance.yahoo.comImplied Volatility Surging for Amphastar (AMPH) Stock OptionsMay 13, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Teva Pharmaceutical (TEVA), Globus Medical (GMED) and DENTSPLY SIRONA (XRAY)May 10, 2024 | finance.yahoo.comAmphastar Pharmaceuticals Reports Strong First Quarter Earnings, Surpassing Analyst Revenue ...May 10, 2024 | finance.yahoo.comAmphastar Pharmaceuticals First Quarter 2024 Earnings: EPS: US$0.90 (vs US$0.54 in 1Q 2023)May 9, 2024 | finanznachrichten.deAmphastar Pharmaceuticals, Inc.: Amphastar Pharmaceuticals to Present at the Bank of America Securities Health Care ConferenceMay 9, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Amphastar Pharmaceuticals (AMPH) and Erasca (ERAS)May 9, 2024 | markets.businessinsider.comAmphastar Pharmaceuticals: Hold Rating Justified Amidst Growth Prospects and Pipeline PotentialMay 9, 2024 | insidermonkey.comAmphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Q1 2024 Earnings Call TranscriptMay 9, 2024 | finance.yahoo.comAmphastar Pharmaceuticals Inc (AMPH) Q1 2024 Earnings Call Transcript Highlights: Robust Growth ...May 9, 2024 | finance.yahoo.comQ1 2024 Amphastar Pharmaceuticals Inc Earnings CallMay 8, 2024 | investorplace.comAMPH Stock Earnings: Amphastar Pharma Beats EPS, Misses Revenue for Q1 2024May 8, 2024 | washingtonpost.comAmphastar: Q1 Earnings SnapshotSee More Headlines Receive AMPH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Amphastar Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/08/2024Today6/13/2024Next Earnings (Estimated)8/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:AMPH CUSIPN/A CIK1297184 Webwww.amphastar.com Phone(909) 980-9484Fax909-980-8296Employees1,761Year FoundedN/APrice Target and Rating Average Stock Price Target$66.00 High Stock Price Target$71.00 Low Stock Price Target$60.00 Potential Upside/Downside+63.2%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)$2.89 Trailing P/E Ratio14.00 Forward P/E Ratio11.24 P/E Growth0.86Net Income$137.54 million Net Margins22.88% Pretax Margin27.46% Return on Equity29.17% Return on Assets12.11% Debt Debt-to-Equity Ratio0.88 Current Ratio2.18 Quick Ratio1.72 Sales & Book Value Annual Sales$644.40 million Price / Sales3.07 Cash Flow$4.24 per share Price / Cash Flow9.54 Book Value$13.35 per share Price / Book3.03Miscellaneous Outstanding Shares48,900,000Free Float35,650,000Market Cap$1.98 billion OptionableOptionable Beta0.82 20 High-Yield Dividend Stocks that Could Ruin Your RetirementAlmost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.Get This Free Report Key ExecutivesDr. Ziping Luo Ph.D. (Age 74)Chairman of the Board, Chief Scientist & COO Comp: $1.53MDr. Yongfeng Zhang Ph.D. (Age 77)Co-Founder, President, CEO, Chief Scientific Officer & Director Comp: $2.13MMr. William J. Peters M.B.A. (Age 56)CFO, Executive VP of Finance, Treasurer & Director Comp: $1.12MMr. Jacob Liawatidewi M.B.A. (Age 50)Executive VP of Sales, Marketing & Corporate Administration Center, Corporate Secretary and Director Comp: $794.15kMr. Rong Zhou M.S. (Age 65)Senior Executive Vice President of Production Comp: $835.05kDan Dischner M.B.A.Vice President of Human Resources & Corporate CommunicationTony Marrs M.B.A.M.P.H., Senior VP of Regulatory Affairs & Clinical OperationsMore ExecutivesKey CompetitorsProtagonist TherapeuticsNASDAQ:PTGXFive Prime TherapeuticsNASDAQ:FPRXSyndax PharmaceuticalsNASDAQ:SNDXCalliditas Therapeutics AB (publ)NASDAQ:CALTPhibro Animal HealthNASDAQ:PAHCView All CompetitorsInsiders & InstitutionsFloyd F PetersenSold 3,000 sharesTotal: $124,200.00 ($41.40/share)Floyd F PetersenSold 500 sharesTotal: $21,325.00 ($42.65/share)Invst LLCBought 5,781 shares on 5/24/2024Ownership: 0.012%EMC Capital ManagementBought 3,113 shares on 5/20/2024Ownership: 0.006%Comerica BankSold 1,179 shares on 5/17/2024Ownership: 0.032%View All Insider TransactionsView All Institutional Transactions AMPH Stock Analysis - Frequently Asked Questions Should I buy or sell Amphastar Pharmaceuticals stock right now? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Amphastar Pharmaceuticals in the last twelve months. There are currently 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" AMPH shares. View AMPH analyst ratings or view top-rated stocks. What is Amphastar Pharmaceuticals' stock price target for 2024? 4 brokers have issued twelve-month price objectives for Amphastar Pharmaceuticals' stock. Their AMPH share price targets range from $60.00 to $71.00. On average, they predict the company's stock price to reach $66.00 in the next year. This suggests a possible upside of 63.2% from the stock's current price. View analysts price targets for AMPH or view top-rated stocks among Wall Street analysts. How have AMPH shares performed in 2024? Amphastar Pharmaceuticals' stock was trading at $61.85 on January 1st, 2024. Since then, AMPH stock has decreased by 34.6% and is now trading at $40.45. View the best growth stocks for 2024 here. When is Amphastar Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 13th 2024. View our AMPH earnings forecast. How were Amphastar Pharmaceuticals' earnings last quarter? Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) released its quarterly earnings data on Wednesday, May, 8th. The company reported $0.93 EPS for the quarter, topping analysts' consensus estimates of $0.73 by $0.20. The firm had revenue of $171.84 million for the quarter, compared to the consensus estimate of $171.13 million. Amphastar Pharmaceuticals had a trailing twelve-month return on equity of 29.17% and a net margin of 22.88%. What ETFs hold Amphastar Pharmaceuticals' stock? ETFs with the largest weight of Amphastar Pharmaceuticals (NASDAQ:AMPH) stock in their portfolio include Invesco Pharmaceuticals ETF (PJP), SPDR S&P Pharmaceuticals ETF (XPH), Janus Henderson Small Cap Growth Alpha ETF (JSML), Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL), ERShares NextGen Entrepreneurs ETF (ERSX), Invesco S&P SmallCap Health Care ETF (PSCH) and iShares U.S. Pharmaceuticals ETF (IHE).SPDR S&P 600 Small Cap ETF (SLY). What is Jack Y. Zhang's approval rating as Amphastar Pharmaceuticals' CEO? 35 employees have rated Amphastar Pharmaceuticals Chief Executive Officer Jack Y. Zhang on Glassdoor.com. Jack Y. Zhang has an approval rating of 35% among the company's employees. This puts Jack Y. Zhang in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies. 48.0% of employees surveyed would recommend working at Amphastar Pharmaceuticals to a friend. What other stocks do shareholders of Amphastar Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Amphastar Pharmaceuticals investors own include Cara Therapeutics (CARA), Gilead Sciences (GILD), Amicus Therapeutics (FOLD), Exelixis (EXEL), CNX Resources (CNX), Immunomedics (IMMU), AbbVie (ABBV), Cellectis (CLLS), Clovis Oncology (CLVS) and Galectin Therapeutics (GALT). Who are Amphastar Pharmaceuticals' major shareholders? Amphastar Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (5.68%), Epoch Investment Partners Inc. (1.66%), Price T Rowe Associates Inc. MD (1.20%), Bessemer Group Inc. (0.82%), Mesirow Institutional Investment Management Inc. (0.73%) and Nordea Investment Management AB (0.68%). Insiders that own company stock include Diane G Gerst, Floyd F Petersen, Howard Lee, Jack Y Zhang, Mary Z Luo, Michael A Zasloff, Richard K Prins, Rong Zhou, William J Peters and Yakob Liawatidewi. View institutional ownership trends. How do I buy shares of Amphastar Pharmaceuticals? Shares of AMPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:AMPH) was last updated on 6/13/2024 by MarketBeat.com Staff From Our PartnersTrump Warns Gov. Can Confiscate Your Money. CBDC's give Gov. absoluteDonald Trump once again sounded the alarm against Fed-controlled digital currencies (CBDCs). If these plans...Monetary Gold | SponsoredThe #1 Crypto That You Don’t Own… YetThere’s all kinds of “signals” to follow when investing in cryptos. But there’s one signal you should pay a...Crypto 101 Media | SponsoredThe Scary Fed Idea To Turn Your Dollars Into a Digital Power GrabCash is becoming a relic of the past… Soon, Biden and the Federal Reserve plan to replace the dollar with t...Oasis Gold | SponsoredGold Prices Surge and This $0.32 Stock Is Reaping The RewardsGold prices are on the rise. This surge in gold prices is great news for gold mining stocks. Especially ...Market JAR | SponsoredEstee Lauder, MAC, and other beauty brands are raving about this emerging NYSE AI companyA Little-known NYSE Company is Empowering the Beauty Industry with Innovative AI and AR Tools.Financial Markets Daily | SponsoredWall Street Icon: "I'd Put 50% of My Kids' Inheritance in THIS stock"Wall Street Icon Warns: "A Great Financial Reset is Underway" The man CNBC called "The Prophet" predicted t...Stansberry Research | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Amphastar Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Amphastar Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.